Search clinical trials for: Neovascular Age-Related Macular Degeneration, Subfoveal CNV, TK001

Total 3079 results

Jiangsu T-Mab Biopharma Co.,Ltd

Unknown

Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration

China
Jiangsu T-Mab Biopharma Co.,Ltd

Unknown

A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration

Neovascular Age-Related Macular Degeneration

China
University of Bern

Completed

iCompassion: Internet-based Self-help for More Self-compassion (iCompassion)

Self-criticism

Switzerland
Kaiser Permanente
Celgene Corporation

Completed

Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer

Prostate Cancer

United States
Ophthotech Corporation

Terminated

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

Age-Related Macular Degeneration

United States
Novartis

Completed

EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Age-Related Macular Degeneration | Choroidal Neovascularization

Taiwan, Korea, Republic of
University of Illinois at Chicago
ICON Bioscience Inc

Completed

20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) (20089/Combo)

Age-Related Macular Degeneration | Choroidal Neovascularization

United States
Alcon Research

Completed

Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)

Macular Degeneration | Age-Related Maculopathies | Age-Related Maculopathy | Maculopathies, Age-Related | Maculopathy, Age-Related
Allergan

Terminated

Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration

Age-Related Maculopathy | Subfoveal Choroidal Neovascularization

United States
Pfizer

Terminated

A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States, United Kingdom, Australia, Netherlands
University Hospital, Basel, Switzerland

Completed

Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV

Age-Related Macular Degeneration | Choroidal Neovascularization

Switzerland
Allergan
Sirna Therapeutics Inc.

Completed

A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Age-Related Macular Degeneration | Choroidal Neovascularization

United States
Novartis

Completed

Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration

Age-Related Macular Degeneration (ARMD)

Switzerland
Manhattan Eye, Ear & Throat Hospital
Alcon Research

Completed

Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.

Age-Related Macular Degenerations. | Subfoveal Neovascularization.

United States
Control Delivery Systems
Bausch & Lomb Incorporated

Unknown

A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration

Macular Degeneration

United States
Eyetech Pharmaceuticals
Pfizer

Completed

Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)

Macular Degeneration

United States
Outlook Therapeutics, Inc.

Recruiting

A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-Related Macular Degeneration | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration

United States
University of Utah
National Eye Institute (NEI)

Recruiting

Impact of Non-Exudative Type 1 MNV on AMD Progression

Age-Related Macular Degeneration | Neovascularization, Choroidal

United States
Perceive Biotherapeutics, Inc.

Recruiting

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Age-Related Macular Degeneration

Australia, Israel
Benobio Co., Ltd.

Not yet recruiting

Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Age-Related Macular Degeneration

Australia
Chengdu Origen Biotechnology Co., Ltd.

Recruiting

Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Age-Related Macular Degeneration

China
Chengdu Origen Biotechnology Co., Ltd.

Recruiting

Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

Age-Related Macular Degeneration

United States
Oslo University Hospital

Not yet recruiting

Photobiomodulation for Dry Age Related Macula Degeneration

Age-Related Macular Degeneration | Photobiomodulation
Benha University

Recruiting

Effect of Corona Virus on Intravitreal Injections

Age-Related Macular Degeneration | Diabetic Retinopathy | Diabetic Macular Edema | Choroidal Neovascularization | Myopic Choroidal Neovascularisation

Egypt
AbbVie

Recruiting

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)

CNV | AMD | nAMD | Wet Age-related Macular Degeneration | wAMD | WetAMD

United States, Puerto Rico, Canada
Theratocular Biotek Co.

Recruiting

A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)

Age-Related Macular Degeneration

Thailand
Novartis Pharmaceuticals

Recruiting

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

Age-Related Macular Degeneration

China, United States, United Kingdom, Puerto Rico
AbbVie

Recruiting

Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)

CNV | AMD | nAMD | Wet AMD | Wet Age-related Macular Degeneration | wAMD

United States
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) (TALON)

Age-related Macular Degeneration

United States, Austria, Czechia, Italy, Taiwan, Belgium, Germany, Australia, Israel, Canada, France, Spain, Korea, Republic of, United Kingdom, Portugal, Netherlands, Sweden, Argentina, Malaysia, Switzerland
The University of Hong Kong

Completed

Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E

Age-Related Macular Degeneration

Hong Kong
Novartis Pharmaceuticals

Completed

Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration (nAMD)

India
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration (FALCON)

Age-related Macular Degeneration

Germany, Switzerland
Novartis Pharmaceuticals

Completed

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study (TALON Ext)

Neovascular Age-related Macular Degeneration

United States, Czechia, Italy, Taiwan, Australia, Israel, Belgium, France, Spain, Germany, Korea, Republic of, Portugal, Sweden, Netherlands, Malaysia, Switzerland
Outlook Therapeutics, Inc.

Active, not recruiting

A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders (NORSE SEVEN)

Age-Related Macular Degeneration | Diabetic Macular Edema | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration | BRVO - Branch Retinal Vein Occlusion

United States
Ophthotech Corporation

Completed

A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

Age-Related Macular Degeneration

France, Israel, Italy, United States, Spain, Portugal, Germany, Austria, Canada, Czechia, Estonia, Latvia, Poland, Slovakia, Australia, Hungary, Croatia, Argentina, Finland, Brazil, Colombia, Norway
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Age-Related Macular Degeneration

Israel, United States, Germany, Denmark, France, Turkey, Hungary, Colombia, Australia, Argentina, Spain
Ophthotech Corporation

Terminated

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Age-Related Macular Degeneration

Italy, Canada, Switzerland, United States, United Kingdom, Austria, Belgium, Brazil, Czechia, Estonia, Latvia, Poland, Slovakia
Ophthotech Corporation

Completed

ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States
Kim's Eye Hospital

Completed

Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV

Age-Related Macular Degeneration | Choroidal Neovascularization | Polypoidal Choroidal Vasculopathy

Korea, Republic of
Adverum Biotechnologies, Inc.

Completed

ADVM-022 Intravitreal Gene Therapy for Wet AMD (OPTIC)

Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States
OcuTerra Therapeutics, Inc.

Completed

Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)

Age-Related Macular Degeneration

United States
University of Utah

Completed

Value of Genetic Counseling and Testing for Patients Who Would Like to Know More About Their Personal Risk of AMD

Age-Related Macular Degeneration | Choroidal Neovascularization | Genetic Counseling

United States
Cinnagen

Completed

Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Age-Related Macular Degeneration | Neovascular Age-related Macular Degeneration

Iran, Islamic Republic of
Adverum Biotechnologies, Inc.

Active, not recruiting

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections (MERLIN)

Age-Related Macular Degeneration

United States, Puerto Rico
Neurotech Pharmaceuticals

Terminated

Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Macular Degeneration

United States, Israel
Outlook Therapeutics, Inc.

Completed

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-related Macular Degeneration | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration

United States
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-Related Macular Degeneration

Korea, Republic of, United States, India, Germany, Hungary, United Kingdom, Czechia, Poland, Russian Federation
Outlook Therapeutics, Inc.

Completed

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-related Macular Degeneration | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration

Australia

Search clinical trials for: Neovascular Age-Related Macular Degeneration, Subfoveal CNV, TK001

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations